David DeLucia

CFO

Equibles does not estimate personal net worth.

Get an email with a short summary when Kyntra Bio, Inc. publishes a filing, an earnings call transcript or a press release.

Get KYNB alerts

About David DeLucia

David DeLucia is recorded as CFO at Kyntra Bio, Inc. (KYNB). The newest filing on record that lists David DeLucia as CFO at Kyntra Bio, Inc. (KYNB) is dated April 27, 2026. Kyntra Bio, Inc. reported in an 8-K filed December 16, 2024 that David DeLucia was appointed Chief Financial Officer, effective December 16, 2024. David DeLucia has spoken on 6 earnings calls across 1 company, most recently for Kyntra Bio, Inc. on August 13, 2026. Kyntra Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kyntra Bio, Inc. includes James A. Schoeneck (CEO), Thane Wettig (CEO and Board Member), Thomas B. Neff (CEO) and 3 others.

“FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024.”

Kyntra Bio, Inc. Form 8-K, filed December 16, 2024 · Read the filing

David DeLucia on recent calls

“For the second quarter of 2026, total revenue was negative $1.5 million compared to $1.3 million for the same period in 2025. Total operating costs and expenses for the second quarter of 2026 were $16.1 million compared to $13.4 million for the second quarter of 2025.”

CFO, Kyntra Bio, Inc. Q2 FY2026 Earnings Call · August 13, 2026

“For the first quarter of 2026, total revenue was $3.7 million compared to $2.7 million for the same period in 2025. Total operating costs and expenses for the first quarter of 2026 were $17.6 million compared to $17.7 million for the first quarter of 2025.”

CFO, Kyntra Bio, Inc. Q1 FY2026 Earnings Call · May 11, 2026

“For the fourth quarter of 2025, total revenue was $1,300,000 compared to $3,100,000 for the same period in 2024. For full year 2025, total revenue was $6,400,000 compared to $29,600,000 for full year 2024.”

CFO, Kyntra Bio, Inc. Q4 FY2025 Earnings Call · March 16, 2026

“I will first review the updated FibroGen China transaction details and then provide the company's financial performance for the third quarter of 2025. As a reminder, our China operations are reflected as discontinued operations throughout our financials.”

CFO, Kyntra Bio, Inc. Q3 FY2025 Earnings Call · November 10, 2025

“I will first review the updated FibroGen China transaction details and then provide the company's financial performance for the second quarter of 2025. As a reminder, our China operations are reflected as discontinued operations throughout our financials.”

CFO, Kyntra Bio, Inc. Q2 FY2025 Earnings Call · August 11, 2025